| Literature DB >> 29753124 |
Remy Morgentin1, Mark Dow2, Anthony Aimon2, George Karageorgis2, Tuomo Kalliokoski3, Didier Roche1, Stephen Marsden4, Adam Nelson5.
Abstract
The identification of high-quality starting points for drug discovery is an enduring challenge in medicinal chemistry. Yet, the chemical space explored in discovery programmes tends be limited by the narrow toolkit of robust methods that are exploited in discovery workflows. The European Lead Factory (ELF) was established in 2013 to boost early-stage drug discovery within Europe. In this Feature, we describe an exemplar partnership that has led to the addition of 21119 distinctive screening compounds to the ELF Joint European Compound Library. The partnership could serve as a blueprint for the translation of innovative academic chemistry into discovery programmes.Mesh:
Substances:
Year: 2018 PMID: 29753124 DOI: 10.1016/j.drudis.2018.05.007
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851